Micafungin
An echinocandin for treating and preventing Candida infections
Micafungin is a semi-synthetic cyclic lipopeptide that blocks the fungal cell-wall enzyme beta-(1,3)-D-glucan synthase. Approved as Mycamine in 2005, it is given by daily intravenous infusion to treat candidaemia and esophageal candidiasis and to prevent Candida infections after stem cell transplants. The brand is discontinued; generics are marketed.
Manufacturer's recommended dosing (FDA label): 100 mg, Once daily, Intravenous, over 1 hour Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
Micafungin is one of four echinocandins, cyclic lipopeptides that block the enzyme fungi need to build the glucan in their cell walls. Human cells lack that enzyme, so the drugs are selective, and they have become first-line treatment for invasive Candida infections in hospitals. FDA approved micafungin as Mycamine on March 16, 2005; generic versions and a ready-to-use premix are now what is marketed.
For treatment, the large trials are equivalence trials. In 531 patients, micafungin matched liposomal amphotericin B for candidaemia, with treatment success of 89.6% and 89.5% in the per-protocol groups. In 595 patients it performed similarly to caspofungin at both the standard dose and a higher one. The dose-response trial in oesophageal candidiasis is where the 150 mg dose comes from.
Prevention is the second use. In 882 patients undergoing stem cell transplantation, it prevented fungal infection better than fluconazole (80.0% against 73.5% overall success). A later randomised trial of 250 transplant patients found no difference in proven or probable infections (7.3% against 8.2%), so the advantage is not consistent. Against posaconazole during leukaemia chemotherapy, prophylaxis failed less often on micafungin (34.5% against 52.7%), mostly because patients tolerated it better rather than because it prevented more infections.
In intensive care, the EMPIRICUS trial gave micafungin empirically to 251 septic patients colonised with Candida. It did not improve survival free of invasive fungal infection at 28 days, though fewer patients developed a new invasive infection (3% against 12%). Waiting for proof of infection remains reasonable. As prophylaxis after high-risk liver transplantation it was non-inferior to standard care, with fewer drug-related adverse events.
Infants are the hardest group. A phase 3 trial against amphotericin B deoxycholate was stopped early after 30 infants, with fungal-free survival of 60% against 70%, too few to show a difference. A separate study of 8 mg/kg daily in 35 neonates resolved most infections. The label approves 4 mg/kg/day for infants under four months with candidaemia only when meningoencephalitis and eye involvement are excluded, because the brain penetration needed is uncertain.
It is given intravenously once daily over an hour, without a loading dose. Steady state is reached after about three doses and the half-life is roughly 13 to 15 hours. As salvage for aspergillosis, a small randomised trial was stopped early without a conclusion, and aspergillosis is not a US indication. The label warns of hypersensitivity, blood, liver and kidney effects, and infusion and injection-site reactions.
Mechanism of Action
Micafungin kills Candida by stopping the fungus from building its cell wall.
Glucan synthase
Inhibits 1,3-beta-D-glucan synthase, the enzyme that makes a key fungal cell-wall polymer (label 12.1 and 12.4).
Selective
Human cells have no glucan cell wall, which is why echinocandins have few target effects in people.
Once daily
Half-life about 13 to 15 hours; about 85% of steady state after three daily doses (label 12.3).
Published Research
The trials behind micafungin, from their PubMed abstracts.
Against liposomal amphotericin B
Among 531 randomised patients with candidaemia or invasive candidiasis, treatment success in the per-protocol analysis was 89.6% on micafungin and 89.5% on liposomal amphotericin B, a difference of 0.7 points, regardless of Candida species, site or neutropenia.
Against caspofungin
In 595 patients, about 85% with candidaemia, treatment success at the end of blinded intravenous therapy was 76.4% on micafungin 100 mg, 71.4% on 150 mg and similar on caspofungin.
Prophylaxis after stem cell transplantation
In 882 adults and children undergoing stem cell transplantation, prophylaxis success was 80.0% on micafungin against 73.5% on fluconazole (difference 6.5 points, P = 0.03).
Esophageal candidiasis dose-response
Endoscopic cure rose with dose, 68.8%, 77.4% and 89.8% on 50, 100 and 150 mg a day; the 100 and 150 mg groups together (83.5%) were comparable to fluconazole 200 mg (86.7%), with similar tolerability.
EMPIRICUS: empirical treatment in ICU sepsis
In 251 non-neutropenic ICU patients with sepsis, Candida colonisation and organ failure, day-28 survival free of invasive fungal infection was 68% on micafungin against 60.2% on placebo (HR 1.35, not significant), though new invasive infections fell (3% against 12%).
Prophylaxis after liver transplant
In 344 high-risk liver transplant recipients, clinical success was 96.5% on micafungin and 93.6% on standard care (non-inferior), with fewer drug-related adverse events (11.6% against 16.3%).
Against fluconazole after transplant
In 250 adults randomised 2:1 after stem cell transplantation, proven or probable fungal infection within 100 days occurred in 7.3% on micafungin and 8.2% on fluconazole, a difference that was not significant; the need to switch antifungal before engraftment was also similar (7.9% against 9.4%).
Against posaconazole in leukaemia
In 113 patients with acute leukaemia or myelodysplastic syndrome receiving chemotherapy, prophylaxis failed in 34.5% on micafungin 100 mg daily and 52.7% on posaconazole suspension. Posaconazole failures were mostly gastrointestinal intolerance; infection rates and survival were similar.
Infants: against amphotericin B
In a phase 3 trial in infants aged 2 to 120 days with invasive candidiasis, stopped early for slow recruitment after 30 infants, fungal-free survival was 60% on micafungin 10 mg/kg/day and 70% on amphotericin B deoxycholate; micafungin exposure exceeded the target.
High dose in neonates
In 35 neonates and young infants with invasive candidiasis given 8 mg/kg daily for about 13 days, infection resolved in 86.7% of those treated for at least 14 days; 20% had a transient rise in liver enzymes.
Salvage for aspergillosis
In a randomised salvage trial for invasive aspergillosis, micafungin 300 mg daily succeeded in 3 of 12 patients against 3 of 5 on standard drugs; the trial was stopped early for low enrolment, and the authors drew no conclusion on efficacy. Aspergillosis is not a US indication.
Dosing Data
Micafungin is a hospital intravenous drug, infused once daily over one hour; the dose depends on the indication, and in children on weight.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Micafungin (injection): For injection: 50 mg single-dose vial. Forms the label lists: single-dose vials.
Source: Micafungin (injection) label, section 3 (DailyMed version 6, effective April 14, 2026).
Mixing a vial: a worked example
The approved product Micafungin (injection) is a powder that is mixed before use, with the liquid and volume its label names. Follow the label, not a general example. Its label says: “Micafungin for injection 50 mg vial: after reconstitution each mL contains 10 mg of micafungin.”
Source: Micafungin (injection) label, sections 2 and 3 (DailyMed version 6, effective April 14, 2026).
Storage before and after mixing
Before mixing or first use: “Unopened vials of lyophilized material must be stored at 20˚C to 25˚C (68˚F to 77˚F); excursions permitted to 15˚C to 30˚C (59˚F to 86˚F).” “Protect from light.”
After mixing or first use: “Store the reconstituted product at 25˚C (77˚F).” “Store the diluted solution at 25˚C (77˚F).” “The reconstituted product should be protected from light and may be stored in the original vial for up to 24 hours at room temperature, 25˚C (77˚F).”
Source: Micafungin (injection) label, sections 16 and 2 (DailyMed version 6, effective April 14, 2026).
How it is taken
As the approved label gives it: Intravenous, over 1 hour (Once daily; Label: candidaemia, disseminated candidiasis, Candida peritonitis and abscesses (adults)).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of about 13 to 15 hours in patients (13.4 h at steady state with candidaemia). After about five half-lives almost none is left.
How long the doses were given: Label: candidaemia, disseminated candidiasis, Candida peritonitis and abscesses (adults): Mean 15 days in responders (range 10-47); Label: oesophageal candidiasis (adults): Mean 15 days in responders (range 10-30); Label: prophylaxis in stem cell transplant recipients (adults): Mean 19 days in responders (range 6-51).
When effects appear: unknown; no source on this page gives a time to effect for Micafungin. Results reported in the studies are under Published Research.
Source: half-life: Micafungin in Sodium Chloride Injection prescribing information, section 12.3 (DailyMed set a95f901e, effective September 29, 2023); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Safety comparable to liposomal amphotericin B and caspofungin in the treatment trials. Full list and cautions ↓
When the label says to stop or get help:
- Hypersensitivity Reactions: Anaphylaxis and anaphylactoid reactions (including shock) have been observed. Discontinue micafungin for injection and administer appropriate treatment.
- Hematological Effects: Isolated cases of acute intravascular hemolysis, hemolytic anemia and hemoglobinuria have been reported. Monitor rate of hemolysis. Discontinue if severe.
- Hepatic Effects: Abnormalities in liver tests; isolated cases of hepatic impairment, hepatitis, and hepatic failure have been observed. Monitor hepatic function. Discontinue if severe dysfunction occurs.
Source: Micafungin (injection) label, boxed warning and section 5 (DailyMed version 6, effective April 14, 2026); the Side Effects section below (“From the studies above”).
Interactions
- sirolimus, itraconazole, nifedipine: monitor for toxicity of these drugs and reduce their dose if necessary
- cyclosporine, itraconazole, voriconazole, fluconazole, rifampin, ritonavir: did not alter micafungin pharmacokinetics
Every peptide's record, with its source: the interaction matrix.
Source: Baxter. Micafungin in Sodium Chloride Injection US prescribing information, section 7. DailyMed version of September 29, 2023, read October 3, 2026.
Checking what you bought
Unknown: no published independent test of Micafungin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Mycamine (Astellas), NDA 021506, on March 16, 2005). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the micafungin label (DailyMed, effective September 29, 2023).
Legal Status
Micafungin is an approved prescription drug in the US.
Frequently Asked Questions
?Is micafungin a peptide?
Yes. Like the other echinocandins it is a cyclic lipopeptide: a ring of amino acids with a fatty side chain, made by modifying a natural fungal product.
?What is micafungin used for?
Treating candidaemia and other invasive Candida infections and esophageal candidiasis, and preventing Candida infections in people undergoing stem cell transplantation.
?Is Mycamine still available?
The Mycamine brand is listed as discontinued in the US, but generic micafungin and a ready-to-use premix are marketed.
?Is micafungin used for mould infections?
Not in the US label. A small randomised salvage trial in invasive aspergillosis was stopped early without a conclusion; its approved uses are Candida infections and prophylaxis after stem cell transplantation.
?Can babies receive micafungin?
Yes. The label covers infants under 4 months with candidaemia at 4 mg/kg daily, provided meningoencephalitis and eye involvement have been excluded. A neonatal phase 3 trial against amphotericin B was too small to show a difference.
?Does it beat fluconazole for prevention after transplant?
Not consistently. One 882-patient trial favoured micafungin (80.0% against 73.5% success), but a 250-patient trial found similar infection rates (7.3% against 8.2%).
References
- [fda] US FDA, Drugs@FDA (openFDA): MYCAMINE, NDA 021506 (March 16, 2005; discontinued); micafungin generics and NDA 216142 (Baxter, September 29, 2023). Read October 3, 2026.
- [fda-pi] FDA. Micafungin in Sodium Chloride Injection US prescribing information (Baxter; DailyMed set a95f901e-0ac4-4ec0-9720-9c6a066cd06c, version 6, effective September 29, 2023). Read October 3, 2026.
- [pubmed] Kuse ER, et al. "Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial." Lancet, 2007;369(9572):1519-1527. PMID: 17482982.
- [pubmed] Pappas PG, et al. "Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis." Clin Infect Dis, 2007;45(7):883-93. PMID: 17806055.
- [pubmed] van Burik JA, et al. "Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation." Clin Infect Dis, 2004;39(10):1407-16. PMID: 15546073.
- [pubmed] de Wet N, et al. "A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients." Clin Infect Dis, 2004;39(6):842-9. PMID: 15472817.
- [pubmed] Timsit JF, et al. "Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial." JAMA, 2016;316(15):1555-1564. PMID: 27706483.
- [pubmed] Saliba F, et al. "Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients." Clin Infect Dis, 2015;60(7):997-1006. PMID: 25520332.
- [clinical-trial] Park S, et al. "Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients." J Infect, 2016;73(5):496-505. PMID: 27394404.
- [clinical-trial] Epstein DJ, et al. "Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study." J Infect, 2018;77(3):227-234. PMID: 29746955.
- [clinical-trial] Benjamin DK Jr, et al. "A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis." Pediatr Infect Dis J, 2018;37(10):992-998. PMID: 29596222.
- [clinical-trial] Auriti C, et al. "High-Dose Micafungin in Neonates and Young Infants with Invasive Candidiasis: Results of a Phase 2 Study." Antimicrob Agents Chemother, 2021;65(4). PMID: 33558294.
- [clinical-trial] Cornely OA, et al. "Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis." Mycoses, 2015;58(1):58-64. PMID: 25530265.
- [fda-pi] Micafungin for injection US prescribing information (Hisun Pharmaceuticals; DailyMed set 230fcff4, version 6, effective April 14, 2026), sections 2.1-2.3 and 12.3; read October 6, 2026.
Sources & Citations
Studies were read from their PubMed abstracts; the label doses from DailyMed (set 230fcff4, effective April 14, 2026), read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.